NCT03719131View on ClinicalTrials.gov

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 5, 2019

Primary Completion Date

September 27, 2022

Study Completion Date

June 30, 2026

Conditions
Cutaneous Melanoma, Stage IIICutaneous Melanoma, Stage IVStage III MelanomaStage IIIA Skin MelanomaStage IIIB Skin MelanomaStage IIIC Skin MelanomaStage IV Skin MelanomaUnresectable Melanoma
Interventions
DRUG

Nivolumab

Receive standard of care nivolumab therapy

BIOLOGICAL

Rituximab and Hyaluronidase Human

Given IV or SC

DRUG

Ipilimumab

Receive standard of care ipilimumab therapy

Trial Locations (1)

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Emory University

OTHER